Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 8Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 8Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Myeloid 2Dermatologic 2Classical hematology 2CNS 2Breast 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1

Conditions

Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer 1Breast Neoplasms 1Body Weight 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hematologic Tests × Breast × Clear all
NCT01834950 2018-03-29

HERBIN

Gustave Roussy, Cancer Campus, Grand Paris

Phase NA Completed
25 enrolled
Breast

Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer

NCT01506466 2015-07-24

Weight Variation During Chemotherapy in Breast Cancer Patients

Centre Jean Perrin

Phase NA Completed
52 enrolled
Breast

Body Weight, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡